130 related articles for article (PubMed ID: 15356820)
1. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Demeter LM; Ribaudo HJ; Erice A; Eshleman SH; Hammer SM; Hellmann NS; Fischl MA;
Clin Infect Dis; 2004 Aug; 39(4):552-8. PubMed ID: 15356820
[TBL] [Abstract][Full Text] [Related]
2. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
Foudraine NA; Jurriaans S; Weverling GJ; Burger DM; Hoetelmans RM; Roos MT; Maas J; Miedema F; Reiss P; Portegies P; de Wolf F; Lange JM
Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
Fischl MA; Ribaudo HJ; Collier AC; Erice A; Giuliano M; Dehlinger M; Eron JJ; Saag MS; Hammer SM; Vella S; Morse GD; Feinberg JE; Demeter LM; Eshleman SH;
J Infect Dis; 2003 Sep; 188(5):625-34. PubMed ID: 12934177
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Shafer RW; Smeaton LM; Robbins GK; De Gruttola V; Snyder SW; D'Aquila RT; Johnson VA; Morse GD; Nokta MA; Martinez AI; Gripshover BM; Kaul P; Haubrich R; Swingle M; McCarty SD; Vella S; Hirsch MS; Merigan TC;
N Engl J Med; 2003 Dec; 349(24):2304-15. PubMed ID: 14668456
[TBL] [Abstract][Full Text] [Related]
6. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
[TBL] [Abstract][Full Text] [Related]
7. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
Mouroux M; Descamps D; Izopet J; Yvon A; Delaugerre C; Matheron S; Coutellier A; Valantin MA; Bonmarchand M; Agut H; Massip P; Costagliola D; Katlama C; Brun-Vezinet F; Calvez V
Antivir Ther; 2001 Sep; 6(3):179-83. PubMed ID: 11808752
[TBL] [Abstract][Full Text] [Related]
8. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.
De Luca A; Cingolani A; Di Giambenedetto S; Trotta MP; Baldini F; Rizzo MG; Bertoli A; Liuzzi G; Narciso P; Murri R; Ammassari A; Perno CF; Antinori A
J Infect Dis; 2003 Jun; 187(12):1934-43. PubMed ID: 12792870
[TBL] [Abstract][Full Text] [Related]
9. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Robbins GK; De Gruttola V; Shafer RW; Smeaton LM; Snyder SW; Pettinelli C; Dubé MP; Fischl MA; Pollard RB; Delapenha R; Gedeon L; van der Horst C; Murphy RL; Becker MI; D'Aquila RT; Vella S; Merigan TC; Hirsch MS;
N Engl J Med; 2003 Dec; 349(24):2293-303. PubMed ID: 14668455
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.
Parkin NT; Lie YS; Hellmann N; Markowitz M; Bonhoeffer S; Ho DD; Petropoulos CJ
J Infect Dis; 1999 Sep; 180(3):865-70. PubMed ID: 10438382
[TBL] [Abstract][Full Text] [Related]
11. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
Antivir Ther; 2002 Mar; 7(1):11-20. PubMed ID: 12008783
[TBL] [Abstract][Full Text] [Related]
12. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.
Rusconi S; La Seta Catamancio S; Citterio P; Bulgheroni E; Kurtagic S; Galazzi M; Croce F; Moroni M; Galli M
Antivir Ther; 2001 Mar; 6(1):41-6. PubMed ID: 11417760
[TBL] [Abstract][Full Text] [Related]
13. Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.
Monpoux F; Sirvent N; Cottalorda J; Mariani R; Lefbvre JC
AIDS; 1997 Oct; 11(12):1523-5. PubMed ID: 9342078
[No Abstract] [Full Text] [Related]
14. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Descamps D; Flandre P; Joly V; Meiffrédy V; Peytavin G; Izopet J; Tamalet C; Zeng AF; Harel M; Lastère S; Aboulker JP; Yéni P; Brun-Vézinet F;
J Acquir Immune Defic Syndr; 2002 Dec; 31(5):464-71. PubMed ID: 12473833
[TBL] [Abstract][Full Text] [Related]
15. HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
Quirino T; Niero F; Ricci E; Pusterla L; Carradori S; Gabbuti A; Iemoli E; Landonio S; Faggion I; Bonfanti P;
Antivir Ther; 2000 Sep; 5(3):195-7. PubMed ID: 11075939
[TBL] [Abstract][Full Text] [Related]
16. Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
Pillay D; Walker AS; Gibb DM; de Rossi A; Kaye S; Ait-Khaled M; Muñoz-Fernandez M; Babiker A
J Infect Dis; 2002 Sep; 186(5):617-25. PubMed ID: 12195348
[TBL] [Abstract][Full Text] [Related]
17. Spring cleaning in trial land.
Gilden D
GMHC Treat Issues; 1997 Mar; 11(3):4-7. PubMed ID: 11364275
[TBL] [Abstract][Full Text] [Related]
18. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
Havlir DV; Hellmann NS; Petropoulos CJ; Whitcomb JM; Collier AC; Hirsch MS; Tebas P; Sommadossi JP; Richman DD
JAMA; 2000 Jan; 283(2):229-34. PubMed ID: 10634339
[TBL] [Abstract][Full Text] [Related]
19. ACTG 320 trial halted as three-drug arm proves superior.
AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361796
[No Abstract] [Full Text] [Related]
20. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
